This study explores how much of the drugs defactinib or VS-6766 reach the brain and their safety in treating glioblastoma, a type of brain cancer. Glioblastomas grow rapidly, partly due to the uncontrolled activity of certain proteins called kinases. Defactinib and VS-6766 help control these proteins to potentially slow down tumor growth. In this study, patients will receive a single oral dose of either drug before their planned tumor surgery. Blood samples and tumor tissue will be collected for analysis.
Key Points:
- The trial involves taking one dose of a study drug before surgery.
- Participants must be adults diagnosed with glioblastoma needing surgery.
- Pregnant women, children, and prisoners are excluded.
Participants will be monitored for safety and how well the drug reaches the brain. They should discuss eligibility and potential risks with their doctor before joining.
How understandable was the trial content above?
Hard to understand
Easy to understand